胚系遗传风险与前列腺癌特异性死亡率:基于人群发病队列研究
中位随访6.73年,1581例(10.8%)死于前列腺癌。BRCA2、MSH6、PALB2等NCCN推荐DNA损伤修复基因及KLK3 I179T变异与PCSM升高独立相关,且该关联在无转移患者中仍显著。
要点
- BRCA2、MSH6、PALB2致病性变异与前列腺癌特异性死亡风险升高独立相关。
- KLK3 I179T变异及7个其他NCCN推荐DDR基因聚合变异亦与PCSM升高相关。
- 14.45%男性携带上述变异,其前列腺癌特异性死亡显著更早,局限期患者中关联仍显著。
核心结论
- 胚系遗传易感性并非均匀增加致死性进展风险。
- NCCN推荐DDR基因致病性变异和KLK3 I179T变异可识别PCSM高风险亚组,包括临床局限期患者。
- 研究支持在诊断时考虑选用特定胚系标志物进行预后风险分层。
研究设计与样本
- 采用Fine-Gray竞争风险模型,校正非前列腺癌死亡。
- 评估11个NCCN推荐基因、9个其他候选基因、2个常见变异(KLK3 I179T和HSD3B1 1245 A>C)及3个多基因风险评分。
主要发现
- 中位随访6.73年,1581例(10.8%)死于前列腺癌。
- BRCA2、MSH6、PALB2致病性变异(Tier-1)各自与PCSM升高相关。
- 7个其他NCCN推荐DDR基因聚合变异(Tier-2)及KLK3 I179T变异亦独立与PCSM相关。
- HOXB13、9个其他候选基因、HSD3B1及3个PRS与累积PCSM风险无关。
- 14.45%男性携带Tier-1或Tier-2致病性变异和/或KLK3 I179T,其前列腺癌特异性死亡显著更早,且在诊断时无转移者中关联仍显著。
关键数值与推荐
- Tier-1基因为BRCA2、MSH6、PALB2。
- Tier-2为7个其他NCCN推荐DDR基因的聚合致病性变异。
- KLK3 I179T变异独立与PCSM相关。
临床怎么用
- 对前列腺癌诊断时考虑检测NCCN推荐DDR基因致病性变异和KLK3 I179T变异以辅助预后分层。
- 携带上述变异的局限期患者可能需更密切随访或个体化管理决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiple germline variants are associated with prostate cancer (PCa) susceptibility and aggressive features; however, their value for predicting prostate cancer-specific mortality (PCSM) at the time of diagnosis remains uncertain, particularly among men with clinically localized disease. METHODS: We evaluated associations between germline risk factors and PCSM among 14,644 men with incident PCa in the UK Biobank. Associations between PCSM and reported germline risk factors, including 11 genes recommended by the National Comprehensive Cancer Network (NCCN), nine other candidate genes, two common variants [KLK3 (I179T) and HSD3B1 (1245 A > C)], and three polygenic risk scores (PRSs), were tested using Fine-Gray competing-risk models accounting for non-PCa mortality. RESULTS: During a median follow-up of 6.73 years after diagnosis, 1581 men (10.8%) died from PCa. PVs in three NCCN-recommended DNA damage-repair genes (BRCA2, MSH6, PALB2) were individually associated with increased PCSM and were defined as Tier-1. Aggregated PVs in seven additional NCCN-recommended DDR genes (Tier-2) and the KLK3 I179T variant were also independently associated with PCSM. In contrast, HOXB13, nine other candidate genes, HSD3B1, and all three PRSs were not associated with cumulative PCSM risk. Overall, 14.45% of men carried Tier-1 or Tier-2 PVs and/or KLK3 I179T and experienced significantly earlier PCa-specific mortality. Importantly, associations remained significant among men without metastatic disease at diagnosis. CONCLUSIONS: Reported inherited susceptibility to PCa does not uniformly confer risk of lethal progression. Germline PVs in NCCN-recommended DDR genes and the KLK3 I179T variant identify a subset of men at elevated risk of PCSM, including those with apparently localized disease. These findings support consideration of selected germline markers for prognostic risk stratification at diagnosis to inform individualized management decisions.
引用
- Lu L, Xu J, Shi Z, et al. Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort. Prostate Cancer Prostatic Dis. 2026. PMID: 42552394. doi:10.1038/s41391-026-01140-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。